Feed aggregator

Amgen and Allergan's MVASI™ (bevacizumab-awwb) and KANJINTI™ (trastuzumab-anns) now available in the United States

World Pharma News - Tue, 07/23/2019 - 10:00
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.).

DNA Microscopy Changes the Way Scientists Analyze DNA

Biospace news - Tue, 07/23/2019 - 02:00
A new technique, DNA microscopy, is allowing scientists to visualize DNA in a way not previously possible. And there isn’t even an actual microscope involved.

Acadia's Nuplazid Fails to Prove Effectiveness in Schizophrenia Trial

Biospace news - Tue, 07/23/2019 - 02:00
In the trial, 396 patients with moderate-to-severe psychotic symptoms related to adult schizophrenia received either Nuplazid or placebo added to their current antipsychotic treatment. The patients receiving Nuplazid showed a consistent trend in symptom improvement but did not hit statistical sig...

How to Demonstrate Your Worth in the Workplace

Biospace news - Tue, 07/23/2019 - 02:00
If you are feeling undervalued at work, it’s productive to think about how you’ve demonstrated your value internally. Here are four ways to demonstrate your worth in the workplace!

ViiV’s Investigational HIV Drug Finds Success in Hard-to-Treat Patient Population

Biospace news - Tue, 07/23/2019 - 02:00
At 96 weeks, 60% of the heavily pretreated HIV patients dosed with ViiV's experimental treatment achieved virologic suppression.

Sanofi Strikes Deal for U.S. Over-the-Counter Rights to Roche’s Tamiflu

Biospace news - Tue, 07/23/2019 - 02:00
Sanofi will be responsible for leading the clinical program and funding all studies needed to support the over-the-counter switch in the United States and will also be responsible for the regulatory submissions.

Zero Gravity May Allow Viable Human Organs to be 3D Printed

Biospace news - Tue, 07/23/2019 - 02:00
"Our ultimate goal is to provide a solution to an organ shortage that causes an average of 20 people per day in the U.S. alone to die waiting for an organ transplant," quoted Rich Boling, the vice-president of corporate advancement at Techshot.

Civica Rx Inks 5-Year Generic Drug Deal with Hikma Pharmaceuticals

Biospace news - Tue, 07/23/2019 - 02:00
Today, Civica Rx announced a five-year deal with London, UK-based Hikma Pharmaceuticals to manufacture and supply Civica’s members with 14 sterile injectable drugs as a private label distributor.

Research Shows Exosomes Potentially Capable of Repairing Damaged Brain Cells

Biospace news - Tue, 07/23/2019 - 02:00
Research recently published by researchers from The Scripps Research Institute in the Proceedings of the National Academy of Sciences found that exosomes play an integral role in the development of neurons and neural circuits. In addition, they are able to fix brain cells damaged by developmental...

New Research Finds Link Between ALS Progression and the Microbiome

Biospace news - Tue, 07/23/2019 - 02:00
Researchers with the Weizmann Institute of Science worked with mice with an ALS-like disease. They found that the course of the disease slowed after the mice received specific strains of gut microbes or substances that were secreted by the microbes. The results suggest that the microbiome may pla...

FDA approves first generics of Lyrica

World Pharma News - Mon, 07/22/2019 - 10:00
On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury.

DURECT and Gilead Collaborate on HIV Therapy in Potential $320 Million+ Deal

Biospace news - Mon, 07/22/2019 - 02:00
“We are pleased to be working on this program with Gilead given their expertise and global leadership in the HIV and HBV fields,” stated James E. Brown, president and chief executive officer of DURECT.

Could a ‘Bio-Belt’ Boost the Economy of Rural America?

Biospace news - Mon, 07/22/2019 - 02:00
For John Cumbers, chief executive officer of SynBioBeta, turning rural America into a biotech hotbed may be an answer to kick start the local economies and advance new products that could benefit the nation and world.

Intec Pharma Crashes as Phase III Parkinson’s Treatment Fails in Comparison Trial

Biospace news - Mon, 07/22/2019 - 02:00
While the trial did not hit its goals, Intec said data review has shown that certain subsets of patients saw a meaningful reduction in OFF time.

InvaGen Receives FDA Approval for Generic of Pfizer's Lyrica

Biospace news - Mon, 07/22/2019 - 02:00
The drug is approved for use for management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, adjunctive therapy for partial-onset seizures in patients 17 years of age and older, fibromyalgia, and neuropathic pain associated with spinal cord injury.

Link Between Diabetes and Arterial Restriction Could Lead to New Treatments

Biospace news - Mon, 07/22/2019 - 02:00
Researchers at UC Davis Health identified a new molecular link that could potentially lead to new diabetes treatments and potential cardiovascular therapies. They published their research in The Journal of Clinical Investigation.

Baxter International Nabs FDA Approval for Insulin IV Infusion

Biospace news - Mon, 07/22/2019 - 02:00
Myxredlin is intended for use only in acute care settings under medical supervision.

FDA Approves First Treatment for Oral Ulcers Associated with Rare Inflammatory Disease

Biospace news - Mon, 07/22/2019 - 02:00
The FDA approval marks the first for oral ulcers associated with Behçet’s Disease and the third for Otezla.

Subcutaneous Formulation of Takeda’s Entyvio Hits the Mark in Crohn’s Trial

Biospace news - Mon, 07/22/2019 - 02:00
Takeda will release complete Phase III data at a future scientific conference and is planning on seeking regulatory approval for the investigational formulation.

The Top 3 Factors That Lead to Happiness at Work

Biospace news - Mon, 07/22/2019 - 02:00
Have you ever wondered why some life science professionals seem very happy at work, and appear to love their jobs? At the same time, their co-workers in an identical position are miserable.